Fig. 7
Effect of metformin and CR plus chemotherapy in subcutaneous K and KL tumors: Tumor growth inhibition in KRASG12D (A, B) and KRASG12D/LKB1del (C, D) subcutaneously injected in immunocompetent mice (N = 9). For three weeks metformin (MET) was administered daily at 300 mg/kg, cisplatin (DDP) 5 mg/kg once a week and caloric restriction (CR) consisted of 36 h of fasting, once a week. Two-way ANOVA was used for statistical analysis (**p < 0.01, ****p < 0.0001). Error bars indicate SEM. The most statistically significant results have been reported in panels A and C. Single treatments, reported in panels B and D, did not induce a statistically significant reduction in tumor growth when compared to control or DDP groups